Tezspire® (Tezepelumab) Approved for Nasal Polyps: A New Option for Chronic Sinusitis Patients

The FDA approval of Tezspire® (tezepelumab) for chronic rhinosinusitis with nasal polyps (CRSwNP) represents an important advancement for patients living with persistent nasal congestion, reduced sense of smell, and recurring sinus symptoms. By targeting the inflammation that contributes to nasal polyp growth, Tezspire offers a new treatment option for patients whose symptoms remain difficult to control with conventional therapies.

Medical Update

• FDA-approved biologic therapy for eligible patients with CRSwNP.
• Targets thymic stromal lymphopoietin (TSLP).
• Designed to reduce nasal polyp growth and inflammation.
• May decrease the need for repeated oral steroids and surgery.
• Supports long-term symptom control and improved quality of life.

What Is Chronic Rhinosinusitis With Nasal Polyps?

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-term inflammatory condition in which soft, non-cancerous growths develop inside the nasal passages and sinuses. These polyps can block airflow, reduce the sense of smell, and contribute to ongoing congestion and facial pressure.

Common Symptoms

• Persistent nasal congestion.
• Reduced or complete loss of smell.
• Facial pressure or sinus discomfort.
• Postnasal drip.
• Difficulty breathing through the nose.

What Is Tezspire?

Tezspire (tezepelumab) is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an important molecule involved in initiating multiple inflammatory pathways associated with chronic sinus inflammation and nasal polyp formation.Unlike traditional treatments that mainly relieve symptoms, Tezspire targets the underlying immune response responsible for ongoing inflammation, offering a more targeted approach for eligible patients.

How Tezspire Works

By blocking TSLP, Tezspire interrupts the inflammatory cascade before it activates several downstream immune pathways. This helps reduce tissue swelling, inflammatory signaling, and the growth of nasal polyps.

• Blocks TSLP activity.
• Reduces inflammatory cytokine release.
• Helps decrease nasal congestion.
• Supports improved airflow and breathing.
• Targets inflammation at its source.

FDA Approval & Clinical Evidence

FDA approval was supported by clinical research demonstrating meaningful improvements in nasal polyp size, congestion, and patient-reported symptoms among eligible individuals with chronic rhinosinusitis and nasal polyps.

Highlights From Clinical Studies

• Reduction in nasal polyp scores.
• Improved nasal airflow.
• Better sense of smell.
• Reduced need for oral corticosteroids.
• Lower likelihood of repeat sinus surgery.

Safety, Side Effects & Eligibility

Clinical studies have shown Tezspire to be generally well tolerated. As with any biologic therapy, treatment should be prescribed and monitored by an experienced healthcare professional.

Common Side Effects

• Injection-site reactions.
• Headache.
• Sore throat.
• Mild upper respiratory symptoms.

Who May Be Eligible?

• Adults with moderate-to-severe chronic rhinosinusitis with nasal polyps.
• Patients whose symptoms remain uncontrolled despite corticosteroids.
• Individuals who continue to experience recurrent nasal polyps after surgery.
• Patients with coexisting asthma who may benefit from broader inflammatory control.

Benefits Compared With Traditional Treatments

While nasal sprays, oral corticosteroids, and surgery remain important treatment options, Tezspire offers a targeted biologic approach designed to address the inflammation that drives chronic nasal polyps.

Potential Advantages

• Targets the underlying inflammatory pathway.
• May reduce the recurrence of nasal polyps.
• Can decrease reliance on repeated oral steroid treatment.
• May lower the need for additional sinus surgery.
• Convenient dosing every four weeks.

Administration & Ongoing Treatment

Tezspire is administered as a subcutaneous injection every four weeks according to the approved prescribing schedule. Regular follow-up appointments help monitor treatment response and ensure ongoing safety.

• Subcutaneous injection.
• Typically administered every four weeks.
• May be given in a healthcare setting or as directed by your provider.
• Routine monitoring supports long-term treatment success.

Insurance & Treatment Access

Coverage for Tezspire varies depending on individual insurance plans. Many insurers require prior authorization, and eligible patients may qualify for manufacturer assistance programs that help reduce out-of-pocket costs.

Clinical Perspective

The approval of Tezspire reflects the continued evolution of precision medicine in allergy and sinus care. By targeting TSLP early in the inflammatory process, specialists have another evidence-based option for patients with chronic rhinosinusitis and nasal polyps whose symptoms remain difficult to control with conventional therapies.

Key Takeaway

Tezspire introduces an important new treatment option for eligible patients with chronic rhinosinusitis and nasal polyps. By addressing inflammation at its source, this biologic therapy offers the potential for improved symptom control, fewer surgeries, reduced steroid use, and a better quality of life.

Find answers to common questions about Tezspire and chronic rhinosinusitis with nasal polyps.